# US 11,304,997 B2 · HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,304,997 B2
- Document ID: US11304997B2
- Status: Granted
- Kind: B2
- Application number: 16/715,758
- Filed: 2019-12-16
- Published: 2020-04-23
- Granted: 2022-04-19
- Earliest claimed: 2014-10-07
- Assignees: Cytlimic Inc.
- Applicants: Cytlimic Inc.
- Inventors: Tomoya Miyakawa; Masaaki Oka; Shoichi Hazama; Koji Tamada; Keiko Udaka
- Web page: https://patentgrep.com/patent/US11304997B2

## CPC

- A61P 35/00: Antineoplastic agents
- C07K 7/06: having 5 to 11 amino acids
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/4262: {Heat shock proteins}
- A61K 47/50: the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61P 37/04: Immunostimulants
- C12N 15/09: Recombinant DNA-technology
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/53: Liver
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 15 and consisting of 11 or less amino acid residues.

## Claims

### Claim 1

A method for inducing an immune response in a subject suffering from cancer, comprising a step of administrating to the subject a peptide consisting of the amino acid sequence of SEQ ID NO: 7.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the peptide can bind to one or more types of HLA molecules.

### Claim 3

A method for inducing an immune response in a subject suffering from cancer, comprising a step of administrating to the subject a pharmaceutical composition comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 7 and a pharmaceutically acceptable formulation component.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the pharmaceutical composition is in the form of a vaccine.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the peptide can bind to one or more types of HLA molecules.